{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","spread":"39.7","upperLimit":"2.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.0","spread":"37.1","upperLimit":"3.6","value":"2.2"},{"groupId":"OG002","lowerLimit":"1.3","spread":"58.4","upperLimit":"6.0","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Alisertib 30 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 30 mg ECT BID 7D"},{"description":"alisertib 40 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG001","title":"Alisertib 40 mg ECT BID 7D"},{"description":"Alisertib 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG002","title":"Alisertib 50 mg ECT BID 7D"}],"paramType":"MEDIAN","populationDescription":"PK evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis. Here number of participants analyzed were participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose","title":"Tmax: Time of First Occurrence of Cmax for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7","type":"PRIMARY","unitOfMeasure":"h"}